Vertaling van "other " (Frans → Nederlands) :

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

Via cette adresse, vous pouvez poser toutes vos questions et faire part de vos remarques concernant la notification de vos produits ou la notification en général (la procédure à suivre, uploadfiles, …). Pour plus d’information sur la notification, vous pouvez consulter le site web de l’INAMI: [http ...]
Hier kan u terecht met alle vragen/opmerkingen met betrekking tot de notificatie van uw producten of de notificatie in het algemeen (de te volgen procedure, uploadfiles, …).

Although the user does not notice it, but he get a (SAML) token that can be used to authenticate with MyCareNet (and other SPs)
Although the user does not

Les listes limitatives et les listes produits admis se trouvent sur le site web de l’INAMI: [http ...]
De limitatieve lijsten en lijsten van aangenomen producten kan u terugvinden op de website van het RIZIV: [http ...]

John Bryson, U.S. Secretary of Commerce, and other senior officials from the Chinese and U.S. governments attended the event.
Mr. Bai Hua, Chairman of Hisun Pharmaceutical, and Dr. Xiaobing Wu, Country Manager of Pfizer China, participated in the signing ceremony.

“ We encourage caregivers and health care professionals to discuss these changes and any others during regular visits”.
“We encourage caregivers and health care professionals to discuss these changes and any others during regular visits”.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.
DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

- - - Collaboration Focused on Addressing Unmet Medical Needs of Patients in Cancer, Cardiovascular, Central Nervous System, and Other Major Therapeutic Areas that Impact the Russian Population
Collaboration Focused on Addressing Unmet Medical Needs of Patients in Cancer, Cardiovascular, Central Nervous System, and Other Major Therapeutic Areas that Impact the Russian Population